Detail akcie Theralase Tech Inc online

Business Summary: Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Theralase Technologies Inc revenues decreased 5% to C$591K. Net loss applicable to common stockholders increased 3% to C$3.4M. Revenues reflect United States segment decrease of 64% to C$38K, International segment decrease of 89% to C$2K. Higher net loss reflects Stock Based Compensation increase of 53% to C$326K (expense), Professional fees increase of 31% to C$276K (expense).